Vertex Pharmaceuticals earns approval for JOURNAVX™ (suzetrigine), a ground-breaking oral NaV1.8 pain channel inhibitor designed to target moderate-to-severe …
Vertex Pharmaceuticals earns approval for JOURNAVX™ (suzetrigine), a ground-breaking oral NaV1.8 pain channel inhibitor designed to target moderate-to-severe …
Despite a cautious capital environment, North American biotech companies secured nearly $2 billion in funding in January 2025, with …
Multiple clinical-stage biotechs unveil bold 2025 roadmaps—from Denali’s upcoming BLA for Hunter syndrome to Cabaletta’s expanding autoimmune cell …
Generative AI has produced a novel TNIK-inhibiting compound now advancing in phase 2a trials—an unprecedented milestone in drug discovery.
Caption By the end of 2024, emerging studies point to GLP‑1 receptor agonists—once mainly weight‑loss drugs—finding versatile application …
The Phase III ENGOT-OV44/First trial delivers a milestone in ovarian cancer research, suggesting immunotherapy could redefine standard of …
On December 19, the clinical research world turns its attention to psychedelic medicine, with new data, global trial …
Moderna’s mRNA-1345 demonstrates 83% efficacy against RSV in adults 60+, positioning it as a frontrunner in next-gen respiratory …
Pfizer’s ambitious gene therapy for Duchenne muscular dystrophy fails to meet efficacy targets, prompting strategic retreat and industry-wide …
Semaglutide’s latest trial reveals significant reduction in heart failure hospitalizations, expanding its role in cardiometabolic care.
Already a subscriber? Log in